our initial public offering. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.
For the three months ended September 30, 2022, we had net income of $993,066, which resulted from gains on the change in fair value of warrant liabilities of $432,286 and interest and dividend income on investments held in Trust Account of $1,160,124, offset in part by the loss on the change in fair value of the forward purchase agreement of $137,259, and operating costs of $462,085.
For the three months ended September 30, 2021, we had a net loss of $30,124, which resulted entirely from operating and formation costs.
For the nine months ended September 30, 2022, we had net income of $9,960,816, which resulted from gains on the change in fair value of warrant liabilities of $9,510,318, interest and dividend income on investments held in Trust Account of $1,472,737, gains on the change in fair value of the forward purchase agreement of $237,459, and unrealized gains on investments held in the Trust Account of $2,900, offset in part by operating costs of $1,262,598.
For the period from February 10, 2021 (inception) through September 30, 2021, we had a net loss of $60,887, which resulted entirely from operating and formation costs.
Liquidity and Capital Resources
Until the consummation of the Initial Public Offering, our only source of liquidity was an initial purchase of founder shares by our Sponsor, for $25,000 and loans from our Sponsor.
As of September 30, 2022, we had $798,833 in cash and working capital of $648,657.
On November 2, 2021, we consummated our Initial Public Offering of 25,000,000 Units, at $10.00 per Unit, generating gross proceeds of $250,000,000. On November 12, 2021, the underwriters of the Initial Public Offering partially exercised their over-allotment option and on November 17, 2021, purchased an additional 1,377,660 Units (the “Over-Allotment Units”), generating gross proceeds of $13,776,600.
Simultaneously with the closing of the Initial Public Offering, we consummated the sale of 8,150,000 private placement warrants (“Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant, in a private placement to our Sponsor, generating gross proceeds of $8,150,000.
Simultaneously with the closing of the exercise of the over-allotment option, the Company consummated the sale of 275,532 additional Private Placement Warrants (the “Over-Allotment Warrants”) at a price of $1.00 per warrant in a private placement to our Sponsor, generating gross proceeds of $275,532.
A total of $263,776,600 of the proceeds of the sale of the Units in the Initial Public Offering, the Over-Allotment Units, the Over-Allotment Warrants and the Private Placement Warrants were placed in the Trust Account at J.P. Morgan Chase Bank, N.A. maintained by Continental Stock Transfer & Trust Company, acting as trustee.
For the nine months ended September 30, 2022, net cash used in operating activities was $695,100, which was due to gains on the change in the fair value of warrant liabilities of $9,510,318, gains on the change in fair value of the forward purchase agreement of $237,459, interest and dividend income on investments held in Trust Account of $1,472,737, and unrealized gains on investments held in Trust Account of $2,900, partially offset by our net income of $9,960,816 and changes in operating assets and liabilities of $567,498.
For the period from February 10, 2021 (inception) through September 30, 2021, net cash used in operating activities was $0, which was due to our net loss of $60,887, which was offset by payments of operating costs through promissory note - related party of $45,500, adjustments for the formation costs paid by Sponsor in exchange for issuance of Class B ordinary shares of $7,866 and changes in accounts payable of $7,521.
There were no cash flows from investing activities for the nine months ended September 30, 2022 and for the period from February 10, 2021 (inception) through September 30, 2021.